Anaveon AG
Immunotherapies for cancer
We are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
06.01.2025
Executive reshuffle in four startups (startupticker.ch)
02.08.2024
Seasoned chairpersons and board members back life sciences startups (startupticker.ch)
11.06.2024
Biotech startups make clinical progress (startupticker.ch)
16.12.2022
The 18 most promising biotech startups, according to investors (TOP 100)
19.09.2022
Encouraging results for Anaveon’s lead molecule (startupticker.ch)
Last Tweets
No milestones
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Anaveon AG
Immunotherapies for cancer
Website:
www.anaveon.com
Headquarter:
Basel
Foundation Date:
December 2017
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
Support received
